JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

JNJ

228.27

-0.51%↓

UNH

369.83

+0.22%↑

TMO

470.55

-1.31%↓

ISRG

459.32

+0.8%↑

ABT

90.03

-0.54%↓

Search

Certara Inc

Suletud

SektorTervishoid

6.17 0.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.12

Max

6.3

Põhinäitajad

By Trading Economics

Sissetulek

-7.4M

-5.9M

Müük

-968K

104M

P/E

Sektori keskmine

100.714

67.147

Kasumimarginaal

-5.688

Töötajad

1,515

EBITDA

8.6M

32M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+44.07% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-77M

957M

Eelmine avamishind

5.35

Eelmine sulgemishind

6.17

Uudiste sentiment

By Acuity

50%

50%

186 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Certara Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 23:08 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 23:07 UTC

Tulu

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:20 UTC

Tulu

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. apr 2026, 23:22 UTC

Tulu

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. apr 2026, 22:52 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:33 UTC

Tulu

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. apr 2026, 22:05 UTC

Tulu

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 21:57 UTC

Tulu

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. apr 2026, 21:55 UTC

Tulu

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. apr 2026, 21:53 UTC

Tulu

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Võrdlus sarnastega

Hinnamuutus

Certara Inc Prognoos

Hinnasiht

By TipRanks

44.07% tõus

12 kuu keskmine prognoos

Keskmine 8.5 USD  44.07%

Kõrge 10 USD

Madal 7 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Certara Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

3

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

11.27 / 12.79Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

186 / 347 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat